PUMA launches Who Gives a Shirt, a new five-part podcast series hosted by former professional footballer Jack Fowler and content creator Kimberley Cumberbatch. The series dives into the powerful cultural, historical and environmental impact of football shirts, exploring how these iconic jerseys shape identity, passion and community – both on and off the pitch. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251002251883/en/PUMA launc...

BT and Infobip have announced the global expansion of their partnership to deliver AI-powered advanced communication services to multinational businesses worldwide. The extended partnership builds on a successful collaboration in the UK, announced in 2022, and combines BT’s Global Voice and inbound contact capabilities with Infobip’s market-leading cloud communications platform. Together, the two companies will drive innovation in global connectivity, providing enterprises with seamless, secu...

Regnology, a global leading software provider of regulatory reporting and supervisory technology solutions, is proud to announce that the Andorran Financial Authority (AFA) has selected the Regnology Supervisory Hub (RSH) hosted on Rcloud to modernize its supervisory operations to meet evolving cross-jurisdictional reporting demands. Founded in 1989, the AFA safeguards the stability of Andorra’s financial sector, including banking entities and insurance companies among other financial activit...

Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration today announced that Swedish Orphan Biovitrum AB (Sobi), a leading international biopharmaceutical company, has elected to implement the Kinaxis Maestro® platform to facilitate end-to-end collaboration across its partner network, enable data-driven decisions and support the delivery of critical therapies to patients with rare diseases. With a mission to serve 95% of rare diseases that still lack approved treatments, ...

Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced a significant milestone in its ongoing Phase 2 clinical study, ACTIVATE (clinicaltrials.gov: NCT05819359), evaluating the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of BIA 28-6156 in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). The ACTIVATE study has enrolled 273 genetically confi...